R&D for Diseases of the Developing World

Collaborating closely with disease experts from non- profit and academic institutions around the globe, CGH has utilized the diverse, drug-like properties of the company’s library of more than 400,000 compounds.

Together with these collaborators and their networks of disease experts, CGH is working to rapidly identify and evaluate candidates for drug development for more than ten diseases that have a devastating impact on families and communities. These strong collaborations are essential to driving long-term progress and prosperity everywhere, including lower- income settings around the world where these diseases are most prevalent.


In 2016, CGH joined the Neglected Tropical Diseases Drug Discovery Booster consortium, a new venture of the Drugs for Neglected Diseases initiative (DNDi), designed to accelerate and reduce the cost of early stage drug discovery for two of the world’s most neglected diseases: leishmaniasis and Chagas disease.

Our participation builds on our long- standing collaboration with DNDi to mine Celgene’s compound library for a range of diseases. CGH and DNDi have collaborated on the screening of CGH’s compound library for activity against NTDs since 2011. Over the last few years, the collaboration has expanded to include the identification and optimization of potential therapeutic candidates for several of the world’s most neglected diseases such as: sleeping sickness, river blindness, and elephantiasis.


CGH has a pipeline with more than ten discovery stage programs and phase II clinical trials in five indications/diseases areas that are ongoing or planned. It is the goal of CGH to not only bring novel therapies to patients in need, but also, to continue to develop a full pipeline for target diseases — just as Celgene does throughout its R&D.

Our global partners and projects include:

  • Medicines for Malaria Venture (MMV): identifying novel therapies for blood and liver-stage malaria
  • H3-D Drug Discovery and Development Center at the University of Cape Town in South Africa: identifying and developing next generation therapies for patients with tuberculosis and malaria
  • GALVmed: the leading not-for- profit global alliance to protect livestock and improve human lives, working on a drug discovery program to advance a Celgene compound with very potent activity against two strains of African Animal Trypanosomiasis (AAT)